Cancer: Antibodies regulate antitumour immunity.

Abstract

Boosting the T cells that mediate anticancer immune responses is a therapeutic goal. But T cells do not work alone — B cells and the antibodies they produce can both trigger and suppress the response. See Letters p.94 & p.99 Oxaliplatin, an immunogenic chemotherapeutic, is effective in aggressive prostate cancer, but as with most other known therapeutics, castration-resistant forms of the cancer become refractory to continued treatment. This study shows that IgA plasmocytes promote resistance to oxaliplatin in prostate cancer mouse models by inhibiting immunogenic tumour cell death and through activation of cytotoxic lymphocytes. Immunosuppressive plasma cells are generated in response to TGFβ, and their functionality depends on the expression of programmed death ligand 1 and interleukin 10. Elimination of these IgA plasmocytes, which also infiltrate human-therapy-resistant prostate cancer, allows cytotoxic-T-cell-dependent eradication of oxaliplatin-treated tumours. Cancers generally evade host immune responses yet tumours are not transmissible between individuals, suggesting that the immune system does have the ability to recognize and kill tumour cells. This study of the fate of transplanted allogeneic tumours in mice shows that their rejection is initiated by naturally occurring tumour-binding IgG antibodies. Fcγ-receptor-mediated uptake of tumour immune complexes into dendritic cells activates tumour-reactive T cells, and intra-tumoral injection of allogeneic IgG together with dendritic cell adjuvants induces systemic T-cell-mediated antitumour responses. This work reveals a novel mechanism of tumour rejection that might be exploited clinically.